Spravato 28 mg Nasal Spray
PDF Leaflet Revision Date: 24 July 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment-resistant depression in adults.
Dosage (summary)
Induction: 56 mg twice weekly for 4 weeks; Maintenance: 56 mg or 84 mg weekly or biweekly.
Onset of Action / Duration
Onset: 30 mins, Duration: 1-2 hours
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; breastfeeding not advised due to potential neurotoxicity.
Key Drug Interactions
- CNS depressants
- Psychostimulants
- MAOIs
Contraindications
- Hypersensitivity to esketamine
- Increased blood pressure risk
- Aneurysmal vascular disease
- Intracerebral hemorrhage
Common side effects
- Dizziness
- Nausea
- Dissociation
- Headache
- Somnolence
Counselling Points
- Avoid hazardous activities post-treatment
- Monitor for suicidal thoughts
- Do not eat/drink before administration
Serious warnings
- Risk of suicidal thoughts
- Transient blood pressure increases
- Potential for dissociation
Important Disclaimer
The Spravato 28 mg Nasal Spray professional information leaflet below is the property of Janssen Pharmaceutica and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
